Caitong International Asset Management’s Gain Therapeutics GANX Stock Holding History

Caitong International Asset Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$335	Buy	+165	New	+$304	﹤0.01%	1869

Other funds holding GANX

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BFA

Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

Caitong International Asset Management's GANX Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Gain Therapeutics (GANX) in Q2 2026: 165 shares worth $335. The stake represents ﹤0.01% of the portfolio and ranks #1869 among its holdings.

10 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Caitong International Asset Management held 165 shares of Gain Therapeutics worth $335 as of Q2 2026.
Gain Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1869 holding.
10 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.